诺和锐30和诺和灵30R治疗2型糖尿病疗效及剂量比较

目的观察CSII强化治疗后的2型精尿病患者改用诺和锐30和诺和灵30R的疗效及剂量比较。方法120例经CSII强化治疗达标（FBG〈7mmol／L，2hBG〈10mmol／L）的2型糖尿病患者随机分为A组：诺和锐30组（60例），B组：诺和灵30R组【对照组，60例）。观察患者日胰岛素总量、血糖控制情况、体质量及低血糖发生率。结果两组患者治疗12周后FBG、PBG2h均调整至正常范围，体质量变化差异无统计学意义。未出现皮疹、发热、瘙痒、肝功损害情况。但A组24小时血糖控制更稳定，日胰岛素用量A组明显少于B组，两组差异有统计学意义，P〈0.01。低血糖和其他不良事件：诺和锐30组低血糖发生率明显少于诺和灵30R组，两组差异有统计学意义，P〈0.01。两组均无严重低血糖事什记录。结论诺和锐30较诺和灵30R能更有效怏速降低血糖，有良好的安全件及依从性。且诺和锐30组剂量明显少于诺和灵30R组。

Comparison of the curative effect and dosage between NovoMix30 and Novolin 30R treating patients with Type 2 Diabetes after the intensification therapy with insulin pump

Objective To study the difference of curative effect and dosage between NovoMix 30 and novolin 30R treating the patients with type 2 diabetes undergoing the intensification therapy with insulin pump. Methods 120 patients with type 2 diabetes undergoing intensification therapy with CSII , whose blood glucose concentration had been up to the standard （FBG〈7mmol/L, 2hBG〈10mmol/L ）, were randomly divided into group NovoMix 30 （60 patients ） （ group A ） and group Novolin 30R （60 patients ） （ gruup B ）.The daily total dosage of insulin, blood glucose concentration,BMI and incidence of hypoglycaemia were observed. Results The level of patients＇FBG and PBG2h in two groups were controlled within the normal limit after 12-week treatment and there was no significantly statistical difference for patients＇BMI between two groups. All patients had no erythra, fever, itching and hepatic lesion. But patients in group A manifested more steady 24h blood glucose and lower daily dosage of insulin compared with those in group B and significant difference was seen between two gn）ups （P〈0.01）. The incidence for hypoglycaemia for patients in group A was lower than that in group B （P〈0.01）.No patient showed severe hypoglycaemia. Conclusion NovoMix 30 decrease blood glucose concentration more effectively and quickly, and shows better safety and compliance （P〈0.01）. The dosage of NovoMix 30 is fewer than that of Novolin 30R obviously.